Genomed S.A.
37.20
PLN
0.00
(0.00%)
ISIN
PLGNOMD00024
Return %
Stock
S&P 500
1Y
24.00
14.20
3Y
3.33
81.12
5Y
-7.00
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Anna Boguszewska-Chachulska
- Full Time Employees
- 56
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Warsaw Poland
- IPO Date
- May 30, 2011
- Website
- genomed.pl
- Similar Companies
- Business
- Genomed S.A. is a Poland-based biotechnology and molecular diagnostics company that specializes in genomic analysis, DNA sequencing, and personalized healthcare solutions. Founded in 2007 and headquartered in Warsaw, Poland, the company operates across the clinical healthcare, life sciences, and medical research sectors. Its core offerings are structured across specialized diagnostic and laboratory services, which include Next-Generation Sequencing (NGS) and Sanger sequencing for clinical diagnostics and biomedical research; non-invasive prenatal testing (NIPT) marketed under the SANCO and SANCO Plus brand portfolios; Whole Exome Sequencing (WES, including Clinical WES and WES MAXIMUM) and Whole Genome Sequencing (WGS) integrated with the proprietary POLGENOM Polish population genomic reference database; targeted diagnostic gene panels for oncology, rare hereditary disorders, cardiology, neurology, and metabolic diseases; custom oligonucleotide, peptide, and RNA synthesis along with molecular biology reagents; and the commercial distribution of specialized laboratory instrumentation, consumables, and automation systems, including 4LAB automated liquid handling workstations. Through its specialized healthcare facility, NZOZ Genomed, the company provides clinical genetic counseling and medical consultations directly to patients. Genomed S.A. serves a diverse client base that includes public and private hospitals, academic medical centers, scientific research institutes, pharmaceutical and biotechnology companies, diagnostic laboratories, and individual consumers across Poland and international markets. In recent operational and strategic developments, the company has expanded its high-throughput sequencing throughput via upgraded Illumina platform integrations and enhanced laboratory process automation; maintained a key strategic partnership and shareholder alignment with Diagnostyka S.A., Poland's largest laboratory network; joined the Employers of Private Medicine association; secured multiple competitive public procurement service contracts with national universities and medical research institutes; and executed corporate capital allocation initiatives including share buyback programs and regular shareholder dividend distributions.